TennesseeControlled Substances - As enacted, authorizes additional healthcare providers to directly administer buprenorphine mono or buprenorphine without the use of naloxone; adds that prescribing a buprenorphine product to nursing mother or prescribing an injectable mono product does not restrict certain healthcare providers from prescribing a buprenorphine product for the treatment of opioid use disorder without naloxone. - Amends TCA Title 53, Chapter 11.
What it does
Plain-language analysis is being updated.
Use the official record and source text while enrichment finishes.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed Senate
- Passed House
- To Governor
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2026
- Apr 24Comp. became Pub. Ch. 753Latest
- Mar 30Companion House Bill substitutedMajor
- Mar 27Placed on Senate Regular Calendar for 3/30/2026
- Mar 18Recommended for passage, refer to Senate Calendar Committee
- Vote recorded SENATE HEALTH AND WELFARE COMMITTEE: Recommended for passage, refer to Senate Calendar Committee 3/18/2026 Passed. Result: pass.Upper
- Mar 17Action deferred in Senate Health and Welfare Committee to 3/18/2026
- Mar 17Placed on Senate Health and Welfare Committee calendar for 3/18/2026
- Mar 11Action deferred in Senate Health and Welfare Committee to 3/18/2026
- Mar 11Placed on Senate Health and Welfare Committee calendar for 3/17/2026
- Mar 4Placed on Senate Health and Welfare Committee calendar for 3/11/2026
- Feb 18Action deferred in Senate Health and Welfare Committee to 3/4/2026
- Feb 11Placed on Senate Health and Welfare Committee calendar for 2/18/2026
- Feb 2Passed on Second Consideration, refer to Senate Health and Welfare CommitteeMinor
- Jan 22Introduced, Passed on First ConsiderationMinor
- Jan 21Filed for introductionIntroduced